Protocol Library - Altai Oncology Software

Altai Protocol Library

Our protocol library curated since 2015 with over 1,000 protocols forms the basis of all our Oncology software solutions

Over 1,000 cancer treatment protocols

Medical Oncology, Hematology, Bone Marrow Transplantation

With administration details, lab parameters, indications, and summarized references

Updated monthly to include latest approvals and major papers

Reviewed by Medical Oncologists and Hematologists

Uterine Cancer

New Indication: Selinexor for Maintenance in Advanced Endometrial Cancer

Ulas D. Bayraktar, MD

Non-Small Cell Lung Cancer

New Indication: Trastuzumab Deruxtecan for her2 Mutant NSCLC

Ulas D. Bayraktar, MD

Biliary Tract Cancer

New Reference: Erdafitinib for Advanced Solid Tumors with FGFR Alterations

Ulas D. Bayraktar, MD

Soft Tissue Sarcoma

New Indication: Atezolizumab for Advanced Alveolar Soft Part Sarcoma

Ulas D. Bayraktar, MD

GastroEsophageal Cancer

New Reference: Pembrolizumab with Chemotherapy in Advanced Gastric Cancer

Ulas D. Bayraktar, MD

Colorectal Cancer

New Protocol: Trifluridine-Tipiracil and Panitumumab for Refractory RAS WT Colorectal Cancer

Ulas D. Bayraktar, MD

Hepatocellular Carcinoma

New Reference: Cabozantinib and Atezolizumab in HCC

Ulas D. Bayraktar, MD

Follicular Lymphoma

New Protocol: Lenalidomide-Rituximab for Untreated Follicular Lymphoma

Ulas D. Bayraktar, MD

Non-Small Cell Lung Cancer

New Indication: Perioperative Nivolumab and Chemotherapy for Stage III NSCLC

Ulas D. Bayraktar, MD

New Indication: Selinexor for Maintenance in Advanced Endometrial Cancer

Phase III, randomised, prospective, multicenter double-blind, placebo-controlled study (ENGOT-EN5/GOG-3055/SIENDO) Patients 18 years or older with histologically confirmed EC, who

Non-Small Cell Lung Cancer

New Indication: Trastuzumab Deruxtecan for her2 Mutant NSCLC

Multicenter, blinded, phase 2 study Previously treated (platinum-containing therapy) patients with HER2m mNSCLC Trastuzumab deruxtecan: 5.4 mg/kg (n=102) vs. 6.4 mg/kg (n=52)

Biliary Tract Cancer

New Reference: Erdafitinib for Advanced Solid Tumors with FGFR Alterations

Phase II, single-arm, multicohort (RAGNAR) Patients aged 12 years or older with advanced or metastatic tumours of any histology (except urothelial cancer) with predefined FGFR1–4

Soft Tissue Sarcoma

New Indication: Atezolizumab for Advanced Alveolar Soft Part Sarcoma

Open-label, multicenter, phase 2 study Unresectable or metasatic ASPS Atezolizumab 1200 mg in adults (n=49) or 15 mg/kg (1200 mg max) in pediatric pts (n=3) once q21 days

GastroEsophageal Cancer

New Reference: Pembrolizumab with Chemotherapy in Advanced Gastric Cancer

Double-blind, multicenter, randomised, phase 3 study (Keynote 859) Previously untreated locally advanced/metastatic HER2 negative GEJ and gastric adenocancer Pembrolizumab + Cht (n

Colorectal Cancer

New Protocol: Trifluridine-Tipiracil and Panitumumab for Refractory RAS WT Colorectal Cancer

Phase II, multicenter (VELO) Patients with refractory RAS WT mCRC Trifluridine-tipiracil +Panitimumab (n=31) vs. Trifluridine-tipiracil (n=31)

Hepatocellular Carcinoma

New Reference: Cabozantinib and Atezolizumab in HCC

Open-label, randomised, phase 3 trial Previously untreated advanced hepatocellular carcinoma Cabozantinib 40 mg plus atezolizumab 1200 mg IV every 3 weeks (N:432), sorafenib 400 mg

Follicular Lymphoma

New Protocol: Lenalidomide-Rituximab for Untreated Follicular Lymphoma

Phase 3, open label, randomized study (RELEVANCE) Untreated grade 1-3a FL R2 (n:513) or R-chemo (n:517), followed by rituximab maintenance

Non-Small Cell Lung Cancer

New Indication: Perioperative Nivolumab and Chemotherapy for Stage III NSCLC

A Phase II , Randomized, Open-label , multicenter trial Resectable, stage IIIA or IIIB NSCLC Arm A: Nivolumab + Carboplatin + PaclitaxelS->Nivolumab (n=57) Arm B: Carboplatin +

Our Solutions

Altai Protocol Library

Our protocol library curated since 2015 with over 1,000 protocols

Altai Oncology Suite

Our premiere, CE-marked, Windows application designed for cancer centers

Altai Oncology App

Easiest access to our protocol library on your hands

Altai Chemo Planner

Core features of Altai Oncology Suite for the solo Oncologist/Hematologist

Articles

Computerized Chemotherapy Order Entry

The Power of a Protocol Library: Standardizing Oncology Care Across Institutions

Oncology care is inherently complex — with evolving treatment regimens, biomarker-specific indications, organ-based dosing, and rapidly changing guidelines. In this landscape, consistency and clarity become essential not only for safety, but also for quality and equity. This is where a centralized protocol library becomes a game-changer …

From Protocol to Pharmacy: Ensuring Seamless Chemotherapy Order Handover

Chemotherapy isn’t just about selecting a protocol — it’s about delivering it safely, on time, and without miscommunication. This article walks through the full treatment workflow from oncologist to pharmacist to infusion nurse, and shows how Altai Oncology creates a unified, structured order that eliminates delays, errors, and manual rework.

Back to top Drag